The FDA approves Wegovy pill, officially ushering in a new era for weight-loss treatment with the first oral version of a blockbuster GPL-1 drug. 

The U.S. Food and Drug Administration's Monday approval of Novo Nordisk's daily pill introduces a convenient alternative to weekly injections for millions, though questions about cost and convenience remain.

FDA Approves Wegovy Pill: A New Convenient Option

The FDA approves the Wegovy pill containing the same active ingredient, semaglutide, as the injectable Wegovy and diabetes drug Ozempic. 

This approval directly addresses patient preference, as studies indicate a significant portion of potential users are hesitant to use injectable medications. 

We believe it will expand access and options for patients, said Dr. Jason Brett of Novo Nordisk. 

Read also: Lisa Rinna’s Daughter Details “Painful” Endometriosis Battle and Surgery

The pill demonstrated comparable efficacy in the trial, showing average weight loss of 14% over 64 weeks, similar to the 15% loss from the injectable version.

FDA Approves Wegovy Pill Amid Looming Competition and Cost Questions

While the FDA approves the Wegovy pill, its market success faces immediate challengers. 

A key rival, Eli Lilly's oral drug orforglipron, expects FDA approval by summer. Analysts suggest Lilly's pill may have a convenience edge, as it can be taken any time without food restrictions, unlike the Wegovy pill, which requires a 30-minute fast before and after dosing. 

On cost, both companies pledged a $ 149 starting price under a government agreement, but the long-term price for higher, maintenance doses is unclear. 

Novo Nordisk has not disclosed its top-tier price, while Lilly stated its highest dose could cost cash-paying patients up to $399.

FDA Approves Wegovy Pill: Expert Perspective on the New Era

Medical experts acknowledge that the FDA approves the Wegovy pill as a significant expansion of options, but note it may not be a definitive breakthrough.

 Columbia University's Dr. Judith Korner stated the pill doesn't seem to be moving the needle that much regarding efficacy, tolerability, or finalized cost for maintenance doses. 

However, the broader trend is transformative. With about 1 in 8 U.S. adults already taking a GPL-1 drug, the arrival of oral forms will likely accelerate adoption. 

The true advancement, experts emphasize, is the proven cardiac and metabolic benefits of this drug class, which now becomes accessible in a more convenient format.

Source of Information: This report is based on the official FDA announcement and subsequent reporting from CNN Health. You can read the original comprehensive coverage here: With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss drugs begins.